期刊
BMC MEDICINE
卷 16, 期 -, 页码 -出版社
BMC
DOI: 10.1186/s12916-018-1103-x
关键词
Epidemiology; Population; NAFLD; NASH
资金
- FP7 Ideas under European Research Council (ERC) [115372]
- National Institute for Health Research (NIHR) Clinician Scientist award [CS-2013-13-012]
- NIHR
- NIHR Biomedical Research Centre, Oxford
- Medical Research Council New Investigator Award
- MRC [MR/N00308X/1] Funding Source: UKRI
Background: Non alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease woildwide. It affects an estimated 20% of the general population, based on cohort studies of varying size and heterogeneous selection. However, the prevalence and incidence of recorded NAFLD diagnoses in unselected real-world healthcare records is unknown. We harmonised health records from four major European territories and assessed age and sex-specific point prevalence and incidence of NAFLD over the past decade. Methods: Data were extracted from The Health Improvement Network (UK), Health Search Database (Italy), Information System for Research in Primary Care (Spain) and Integrated Primary Care Information (Netherlands). Each database uses a different coding system. Prevalence and incidence estimates were pooled across databases by random-effects metaanalysis after a log-transformation. Results: Data were available for 17,669,973 adults, of which 176,114 had a recorded diagnosis of NAFLD. Pooled prevalence trebled from 0.60% in 2007 (95% confidence interval: 0.41-0.79) to 1.85% (0.91-2.79) in 2014. Incidence doubled from 1.32 (0.83-1.82) to 2.35 (1.29-3.40) per 1000 person-years. The FIB-4 non-invasive estimate of liver fibrosis could be calculated in 40.6% of patients, of whom 29.6-35.7% had indeterminate or high-risk scores. Conclusions: In the largest primary-care record study of its kind to date, rates of recorded NAFLD are much lower than expected suggesting under-diagnosis and under-recording. Despite this, we have identified using incidence and prevalence of the diagnosis. Improved recognition of NAFLD may identify people who will benefit from risk factor modification or emerging therapies to prevent progression to cardiometabolic and hepatic complications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据